Love the work

Happy to finally see a promising treatment for RP coming towards the clinic.lets go BlueRock'

Same old story for last 4 years.

It's a bioshell. Another cheat biotech. See where its stock price is. Don't invest in this garbage.

So this guy still hasn't publicly came out to acknowledge that Excision BioTherapeutics EBT-101 was a complete failure in terms of curing HIV or even slowing viral replication.

When will this happen?

Anyone know what are the updates on this? A large community having cone rod dystrophy is waiting for the outcome.

I think there was an error in the upload, it ends after 22seconds

Please do it fast

This company is now "KAPUT". Let the lawsuits begin

Yaaayyy🎉

Will you make hair loss problem solution in this generation 😂

good stock to invest in. wish I knew about Krystal in 2018

My husband suffering from cone destrophy please help me out

Hi what is the treatment for cone destrophy we are from India

💉💀

I have been attending or watching presentations on retinitis pigmentosa for approximately 15 years. I am dismayed by the slowness of the progress. Hopefully, researchers will feel a sense of urgency with this research. As noted in this presentation, there is a point in the progression of RP beyond which this technique does not work. The dreams, hopes, and lives of many persons depend on rapid research success.

I hope they collaborate

amazing talk thank you

Where are they getting skin, blood, and ogans from? And Chimeras?

Go go go! Milk that beauty industry to fund research for rare diseases!

I am Praying every day!! It is so Painful a Life with hearing loss, hyperacusis, Tinnitus And Pain! Please help us. Please ❤️🙏🏼

When is this available in Mexico?

Will it be possible to replace dead tissue that was removed in a debridement from a pilonidal cyst ??? 😢😢😢😢😢😢 The removal of the deeper tissue maybe fascia has really thrown off my balance and causes pain in hip and knee Etc etc

As a liver patient, this presentation was greatly valuable. I wish we could get a more accurate timeline though! Millions of patients are counting on this macrophage therapy!

Sounds great but its disappointing to know that the cell pouch Sernova will use is made of woven polypropylene mesh which is known to cause severe long term side effects. This is seen in hiatal hernia post op surgery patients using this same material. So while someones type 1 maybe cured they could be left with something just as harmful in the long run. One step forward two steps back 🤷‍♂.

Where can these treatment?

🤣

Wow. Amazing

IMPORTANT 14 MIN

Frank Reynolds was ousted from In Vivo Therapeutics in August 2013 for using company funds for his own personal use and for being in general a tyrant and bully to staff (and don't listen to him baloney about being paralyzed and willing himself to walk again--it was all a lie). He subsequently established another company (Pixar Bio) to develop a pain medication delivery platform. Unfortunately, Reynolds was ultimately convicted of securities fraud in 2021 and sentenced to 7 years in prison (where he died in January 2022). The "illustrious" Robert Langer took part in promotional videos for Reynolds scam company (PixarBio) which made him just as culpable in all of this. And as for In Vivo Therapeutics their scaffold failed miserably in clinical trials and the company filed for Chapter 11 bankruptcy in February 2024. I was an investor in In Vivo and was not made aware of Reynolds' shenanigans and I have contacted the SEC to see what can be done. Otherwise, I will have lost all of my investment in this garbage.

This is super exciting stuff! Wishing them the best and hoping they make hair loss a problem of the past!

My mother is on there!

Have you started testing?

I’m cheering for this company and pray that they succeed. My family member has systemic scleroderma with lung involvement and I worry about a future where they are gone.

Keep up this amazing work. Pray for your safety, and success. So many lives depend on this.

Hopefully its a success!

আপনারা গরীব যদি দেশকে উদ্ধার করেন তাড়াতাড়ি মানুষের এই চিকিৎসা পাচ্ছে না তাই আপনাদের সহায়তা

Die Möglichkeit Parkinson zu heilen. Bis heute kann man nur die Symptome mehr recht oder schlecht beeinflussen.

সারা পৃথিবী এই ওষুধের জন্য মনে হয় দু-তিন কোটি 4-5 কোটি মানুষ মারা যেতে পারে

Congratulations!

সারাবিশ্বের মধ্যে আপনার মত ভালো মানুষ নাই আপনারা তাড়াতাড়ি মানুষকে বাঁচান জিন গরিব দেশগুলো অসহায় এর মধ্যে সবাই চা জিন

সারা বিশ্বের আপনার কাছে সবাই দোয়া রইল আপনারাই হেতি দই দয়া করে মানুষকে তাড়াতাড়ি জিন থেরাপি

Huge news will be fantastic when/if this comes to fruition

Stem cells from CCR5Δ32 gene mutation from collected samples modified to be universally adaptable CCR5Δ32 stem cells, combined with Excision Bio-Therapeutics' pending HIV functional/sterilizing therapeutic cure, EBT-101 would mostly equate to a sterilizing HIV cure and an eradication of the virus in the human body. [1]. *Excision BioTherapeutics' EBT-101* The pending HIV functional/sterilizing therapy, *EBT-101, developed by Excision BioTherapeutics. Stated by Excision BioTherapeutics' CEO is Daniel Dornbusch, EBT-101 has the potential to eliminate HIV, and EBT-101 is currently in human clinical trials. In September 2022, Excision BioTherapeutics dosed their first participant in the EBT-101 Phase 1/2 Trial. EBT-101 is CRISPR-based, single administered therapy, designed to cut and removing HIV DNA out of human cells. This potential gene editing treatment employs an adeno-associated virus to deliver CRISPR-CAS9 nucleases and dual guide RNAs targeting three sites within the HIV genome that tell the enzymes where to cut. EBT-101 was initially developed by Dr. Kamel Khalili and researchers at Temple University, located in Philadelphia, Pennsylvania. Excision BioTherapeutics received an FDA Fast Track Designation, for EBT-101. The Fast Track Designation is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. This process is designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy. With the FDA granting Excision BioTherapeutics a Fast Track Designation for EBT-101. Hopefully, EBT-101 will be available for distribution in a couple of years, as the first three patients were infected with EBT-101 that seeks and destroys lingering pieces of HIV in the body. The first EBT-101 human clinical Phase I/II trial (NCTO5144386) started last year in September 2022. At a recent November 20233 presentation in Brussels, Professor Rachel Presti of Washington University St. Louis School of Medicine reported that all three participants in the first dose cohort, regarding EBT-101, have now received HIV therepy. The initial results indicated that no serious adverse events ir dose-limiting toxicities. There were four mild adverse events that nay have been related to the gene therapy, however all were resolved. Two participants experienced transient liver enzymes elevations. None of the three withdraw from the study. EBT-101 was detectable in the blood of all participants four weeks after receiving a single IV infusion using the first dose level to be evaluated. There was no evidence of "horizontal transmission of gene vector shedding of EBT-101 in two tissue compartments associated with male reproductive function", suggesting the therepy is not passed on in semen, according to Excision BioTherapeutics. These findings support testing of a higher dose of EBT-101 in a second cohort of six people, which will happen this year. Dr. William Kennedy, Excision BioTherapeutics' Senior Vice President of Clinical Development stated in a press release the " Establishing the safety and bio-distribution of EBT-101 is an important first step in the clinical program. These initial observations provide important clinical data that support the advancement of the EBT-101-001 trial to the next dosing cohort". The study participants in the EBT-101-001 trial will be followed fir 48 weeks after EBT-101 us administration, and those who are eligible will be assessed for sustained viral suppression after stopping antiretrovirals in an analytical treatment interruption starting at week 12. The first participant, who received EBT-101 in the sumner of 2022, is already well past the 12-week mark, but Excision BioTherapeutics has not provided any further information about his status. [2]. *Modified CCR5Δ32 Stem Cell Infusion* Currently, bone marrow transplant from CCR5Δ32 mutated cells is a procedure that infuses healthy blood-forming stem cells wihich an HIV-positive subject receives a bone marrow transplant from compatible donor who us homozygous for mutations in the HIV receptor CCR5 that result in resistance to HIV infection. Stem Cells Transplant procedures from donors with CCR5Δ32 cell mutation has been documented to have medically cured numerous individuals with HIV, although this procedure comes with with possible risk. Patients receiving a stem cell from a doner with a *CCR5Δ32 mutation* , which blocks HIV from infecting the body. With these stem cell bone marrow transplants, involving the CCR5Δ32 mutation from a donor is a complicated procedure, normally reserved for cancer patients, and comes with many risks, and is too risky to offer it as a option as an HIV cure for everyone. Some individuals were born with the CCR5Δ32 mutation, which naturally blocks HIV, there were those that are considered LTP (Long-term Progressors), which they will carry HIV for decades before their HIV progress to AIDS (with HIV medications). As of 2023, there have been over five documented cases of HIV positive individuals be totally cured from HIV after completing this procedure.

I have al amyloidosis and multiple Myeloma. Is there something coming up to remove amyloid proteins from heart, kidneys and other organs? How about multiple Myeloma. I would also be interested in clinical trials.

Need this for stargardt too!

Well presented. Steve really resisted the urge to talk too fast while still managing to get all the points across.

Thank❤you